CD47 and lymphoma: However, overexpression of CD47 has been discovered in numerous solid tumors and hematologic malignancies, for example, breast cancer, non-small cell lung cancer (NSCLC), and lymphoma, which can lead to immune escape and forecasts poor outcomes [10,11].